2
Total investments
1
Early stage
1
Mid stage
0
Late stage
2y
Years active
Portfolio
2 investments · sorted by recency
All investments
Early stage
Mid stage
Late stage
Seed Investor & Advisor
Oct 2024
The Big Whale is the European reference for Market Intelligence on digital assets.
We deliver trusted data, research, and insights to help you understand, anticipate, and act on the digital asset economy.
Serie A investor
Apr 2024
Ziwig Biotech is a biotechnology company pioneering the analysis of salivary RNA and the application of artificial intelligence to biomolecular biology.
At the crossroads of medicine, data science, and digital technology, Ziwig develops non-invasive tests and therapeutic biomarkers designed to transform the diagnosis and management of chronic diseases—particularly those affecting women.
Its flagship innovation, Endotest®, is the first non-invasive and highly reliable saliva-based test for the diagnosis of endometriosis. This breakthrough innovation, multiple award-winner (Galien Prize, Tech For Future Award), exemplifies Ziwig’s ability to revolutionize women’s health through the convergence of biotechnology, artificial intelligence, and precision medicine.
Ziwig operates at the heart of a rapidly evolving global health ecosystem, where universal access to diagnosis and prevention is a major challenge for equity and sustainability.
Through its scientific and societal commitment, Ziwig contributes to building a more human, accessible, and universal precision medicine—serving patients, healthcare professionals, and the health systems of the future.
🌐 www.ziwig.com
Experience · 2 entries
All (2)
Investments (2)
2024
Seed Investor & Advisor
Oct 2024
The Big Whale is the European reference for Market Intelligence on digital assets.
We deliver trusted data, research, and insights to help you understand, anticipate, and act on the digital asset economy.
Serie A investor
Apr 2024
Ziwig Biotech is a biotechnology company pioneering the analysis of salivary RNA and the application of artificial intelligence to biomolecular biology.
At the crossroads of medicine, data science, and digital technology, Ziwig develops non-invasive tests and therapeutic biomarkers designed to transform the diagnosis and management of chronic diseases—particularly those affecting women.
Its flagship innovation, Endotest®, is the first non-invasive and highly reliable saliva-based test for the diagnosis of endometriosis. This breakthrough innovation, multiple award-winner (Galien Prize, Tech For Future Award), exemplifies Ziwig’s ability to revolutionize women’s health through the convergence of biotechnology, artificial intelligence, and precision medicine.
Ziwig operates at the heart of a rapidly evolving global health ecosystem, where universal access to diagnosis and prevention is a major challenge for equity and sustainability.
Through its scientific and societal commitment, Ziwig contributes to building a more human, accessible, and universal precision medicine—serving patients, healthcare professionals, and the health systems of the future.
🌐 www.ziwig.com